Company intelligence / Profile preview

Quantum Immunologics

Tampa, Florida, United Statesbiospace.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Quantum Immunologics developed a proprietary dendritic cell-based immunotherapy targeting the oncofetal antigen/immature Laminin Receptor Protein (iLRP), with a Phase 1 clinical trial in metastatic breast cancer. The trial status is unknown and no published efficacy results are available. The company filed provisional patents for peptide sequences derived from iLRP to enhance specificity and immunogenicity of their approach. As of the latest reports, the company is out of business.

Therapeutic areas: Oncology
Modalities: Dendritic cell therapyPeptidesVaccineCell therapy
Industry: Biotech

Partnerships

University of South Alabama (originator organization for technology/trial collaboration)

Beyond the preview

Go deeper on Quantum Immunologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantum Immunologics.

Explore the full profile